NR3C2 and Adrenal insufficiency: However, whether they are successful due to the general supportive benefits of glucocorticoids in critically ill patients, mitigation of the cytokine release syndrome and ARDS [12,16], the treatment of undiagnosed adrenal insufficiency (AI) [17,18], or the suppression of endogenous cortisol secretion with reduced effects on mineralocorticoid receptors [19] has yet to be clarified [20].